Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis.

Forty-one patients were included. The majority (n=30; 73.2%) had failed (ineffectiveness) on other targeted-therapies, including JAK-inhibitors (n=14, 34%) and biologics (n=16, 39%). Abrocitinib treatment resulted in a significant decrease of disease severity during a median follow-up period of 25 weeks (IQR 16-34). Median EASI score at baseline decreased from 14.7 (IQR 10.4-25.4) to 4.0 (IQR 1.6-11.4) at last review (p<0.001). Median NRS itch decreased from 7.0 (IQR 5-8) to 3.0 (IQR 1-2) at last review (p<0.001). The most frequently reported AEs included gastrointestinal symptoms (27.6%), acne (20.7%) and respiratory-tract infections (17.2%). Sixteen (39%) patients discontinued abrocitinib treatment due to ineffectiveness, AEs or both (41.2%, 41.2% and 11.8%, respectively) CONCLUSION: Abrocitinib can be an effective treatment for patients with moderate-to-severe AD in daily practice, including non-responders to other targeted therapies.